Roivant reports $252.4 million Q4 loss, widening from $95.0 million a year earlier
Roivant reported a loss from continuing operations of $252.4 million for the three months ended March 31, 2025, compared with a $95.0 million loss a year earlier, on revenue of $7.6 million versus $9.0 million. For the fiscal year, it reported a $729.8 million loss from continuing operations, compared with income of approximately $4.5 billion in the prior year, which included a gain on the Telavant net assets sale. The company repurchased $1.3 billion of shares, cutting outstanding shares by 14%, and ended the period with $4.9 billion in cash, cash equivalents, restricted cash and marketable securities.
Key points
- Q4 revenue was $7.6 million versus $9.0 million a year earlier; R&D expenses rose to $145.2 million from $107.6 million
- Fiscal year loss from continuing operations of $729.8 million, compared with income of approximately $4.5 billion in fiscal 2024
- Share repurchases of $1.3 billion as of March 31, 2025, reducing outstanding shares by 14% from March 31, 2024
- Cash, cash equivalents, restricted cash and marketable securities of $4.9 billion at March 31, 2025
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 29, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.